Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.

The oncologist - 1 Feb 2007

Toschi Luca, Cappuzzo Federico

Abstract excerpt

The epidermal growth factor receptor (EGFR) is implicated in cancer progression and development and, being overexpressed in a variety of human malignancies, is an attractive target for selective anticancer therapy. EGFR tyrosine kinase inhibitors (TKIs) have been demonstrated to produce dramatic and durable responses in a fraction of non-small cell lung cancer patients. During the last few years, clinical and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to ErbB Receptors
Share to EGFR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 17296817
DOI: 10.1634/theoncologist.12-2-211

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.PMID 17296817Read ↗

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.Semantic proximity Read ↗

Genetic alterations shaping tumor response to anti-EGFR therapies.Semantic proximity Read ↗

Lung cancer genetics and pharmacogenomics.Semantic proximity Read ↗

EGFR inhibitors: what have we learned from the treatment of lung cancer?Semantic proximity Read ↗

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.Semantic proximity Read ↗

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.Semantic proximity Read ↗

The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.Semantic proximity Read ↗

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.Semantic proximity Read ↗

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.Semantic proximity Read ↗

Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis.Semantic proximity Read ↗

Mutations and response to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.